Bacitracin + Neomycin + Polymyxin B
47 adverse event reports submitted to the FDA
Active Ingredients
Administration Routes
Species Affected
Most Affected Breeds
Most Reported Reactions
Outcome Breakdown
Data Summary
| Metric | Value |
|---|---|
| Total adverse event reports | 47 |
| Reports involving death | 6 |
| Case-fatality rate (reported events) | 1280.0% |
| Distinct species in reports | 3 |
| Distinct breeds in reports | 20 |
| Distinct reactions reported | 20 |
| Active ingredients on file | 4 |
Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.
Bacitracin + Neomycin + Polymyxin B Adverse Event Insights
The FDA Center for Veterinary Medicine database currently holds 47 adverse event reports referencing Bacitracin + Neomycin + Polymyxin B, including 6 reports in which the animal died — a 1280.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Bacitracin, Bacitracin + Neomycin + Polymyxin B, Neomycin, Polymyxin B. Reported administration routes include Unknown, Ophthalmic, Topical, Intraocular. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.
The species most frequently named in Bacitracin + Neomycin + Polymyxin B reports are Dog (35 reports), Cat (11 reports), Horse (1 reports), with Dog accounting for the largest share. Within those species, Domestic Shorthair (9), Crossbred Canine/dog (5), Pug (5) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.
The most commonly reported clinical signs associated with Bacitracin + Neomycin + Polymyxin B are Corneal ulcer (13), Vomiting (11), Diarrhoea (11), Lethargy (see also Central nervous system depression in Neurological) (9). Of the 47 reports with a coded outcome, Ongoing is the leading category at 53.2%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Bacitracin + Neomycin + Polymyxin B.
Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates
Read our methodology — how this data is sourced, computed, and verified.